pentachlorophenol has been researched along with Thrombosis in 7 studies
PENTA: structure given in first source
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It strongly inhibited thrombus formation in experimental models of thromboplastin/stasis-induced venous thrombosis in rats (IV) and rabbits (SC) (ED50 values = 40." | 3.70 | Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. ( Bernat, A; Hérault, JP; Herbert, JM; Hoffmann, P; Lormeau, JC; Meuleman, DG; Petitou, M; van Amsterdam, RG; van Boeckel, C, 1998) |
| " It strongly inhibited thrombus formation in an experimental model of thromboplastin-induced venous thrombosis in rats (intravenously) and rabbits (subcutaneously) (ED50 values were 25." | 3.69 | Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin. ( Bernat, A; Hérault, JP; Herbert, JM; Lormeau, JC; Meuleman, DG; Petitou, M; van Amsterdam, RG; Vogel, GM, 1996) |
| "This study compares the pharmacokinetic and the antithrombotic properties of two pentasaccharides with high affinity to antithrombin III with those of a conventional low molecular weight heparin, CY216, in the rabbit." | 1.29 | Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ( Boneu, B; Caranobe, C; Carrie, D; Houin, G; Lormeau, JC; Meuleman, D; Petitou, M; Saivin, S; Van Boeckel, C, 1994) |
| "Thrombosis was produced in a two-component thrombogenic device incorporated into an exteriorized femoral arteriovenous (AV) shunt in baboons; the proximal component constituted a segment of collagen-coated tubing and induced platelet-rich arterial-type thrombus, while the distal component consisted of an expanded chamber producing static and disturbed flow and initiated fibrin-rich venous-type thrombosis." | 1.29 | Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. ( Cadroy, Y; Hanson, SR; Harker, LA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrie, D | 1 |
| Caranobe, C | 1 |
| Saivin, S | 1 |
| Houin, G | 1 |
| Petitou, M | 4 |
| Lormeau, JC | 5 |
| Van Boeckel, C | 2 |
| Meuleman, D | 1 |
| Boneu, B | 1 |
| Cadroy, Y | 1 |
| Hanson, SR | 1 |
| Harker, LA | 1 |
| Herbert, JM | 4 |
| Hérault, JP | 3 |
| Bernat, A | 3 |
| van Amsterdam, RG | 2 |
| Vogel, GM | 1 |
| Meuleman, DG | 2 |
| Duchaussoy, P | 1 |
| Jaurand, G | 1 |
| Gourvenec, F | 1 |
| Lederman, I | 1 |
| Strassel, JM | 1 |
| Bârzu, T | 1 |
| Crépon, B | 1 |
| Amiral, J | 1 |
| Marfaing-Koka, A | 1 |
| Vissac, AM | 1 |
| Wolf, M | 1 |
| Boyer-Neumann, C | 1 |
| Tardy, B | 1 |
| Meyer, D | 1 |
| Hoffmann, P | 1 |
| Bassand, JP | 1 |
1 review available for pentachlorophenol and Thrombosis
| Article | Year |
|---|---|
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2000 |
1 trial available for pentachlorophenol and Thrombosis
| Article | Year |
|---|---|
Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.
Topics: Autoantibodies; Cross Reactions; Enzyme-Linked Immunosorbent Assay; Female; Fibrinolytic Agents; Hep | 1997 |
5 other studies available for pentachlorophenol and Thrombosis
| Article | Year |
|---|---|
Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
Topics: Animals; Antithrombin III; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Male; Nadroparin; Oli | 1994 |
Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates.
Topics: Animals; Antithrombin III; Blood Platelets; Enzymes, Immobilized; Factor Xa Inhibitors; Fibrinolytic | 1993 |
Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
Topics: Animals; Anticoagulants; Electric Stimulation; Factor Xa Inhibitors; Fibrinogen; Fibrinolytic Agents | 1996 |
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
Topics: Animals; Antithrombin III; Factor Xa Inhibitors; Fibrinolytic Agents; Half-Life; Humans; Hydroxylati | 1997 |
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
Topics: Animals; Carbohydrate Sequence; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic | 1998 |